Insulet Corporation Reports Strong Q4 2025 Earnings with Continued Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Should l Buy PODD?
Source: seekingalpha
- Sustained Growth: Insulet reported $784 million in revenue for Q4 2025, reflecting a 29% year-over-year increase, marking the tenth consecutive year of over 20% revenue growth, showcasing its robust recurring revenue model and profitability.
- Market Expansion: The company achieved record new customer starts for Omnipod 5 in both U.S. and international markets, particularly in the type 2 diabetes segment, with the prescriber base expanding by 62% to over 6,500 clinicians, underscoring its leadership in diabetes management.
- Increased R&D Investment: R&D spending surged by 50% in Q4 2025, with plans to further increase investments in 2026 to advance next-generation platforms, including Omnipod 6 and a fully closed-loop system, aimed at enhancing patient experience and clinical outcomes.
- Optimistic Outlook: Insulet expects Omnipod revenue to grow by 21% to 23% in 2026, with total company revenue projected to increase by 20% to 22%, alongside an anticipated adjusted EPS growth of over 25%, reflecting strong confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 246.340
Low
316.00
Averages
375.83
High
450.00
Current: 246.340
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insulet Stock Rises 10% Following Strong Q4 Results
- Stock Performance: Insulet shares increased by 10% following the release of their Q4 results.
- Earnings Report: The company's Q4 results exceeded market expectations, contributing to the rise in stock value.
See More
US Stocks Close Higher on Strong Economic Data
- Strong Economic Data: US December capital goods new orders rose 0.6% month-over-month, exceeding expectations of 0.3%, indicating a rebound in capital spending that boosts market confidence and drives stock prices higher.
- Housing Market Recovery: December housing starts increased by 6.2% month-over-month to 1.404 million, significantly surpassing the expected 1.304 million, suggesting a recovery in the housing market that could stimulate investment and consumption in related sectors.
- Manufacturing Production Growth: January manufacturing production rose by 0.6% month-over-month, stronger than the expected 0.4%, marking the largest increase in 11 months, indicating a recovery in manufacturing that supports overall economic growth expectations.
- Optimistic Stock Market Performance: Over 75% of S&P 500 companies reported earnings that beat expectations, with Q4 earnings growth projected at 8.4%, providing strong support for the stock market despite lingering doubts about future interest rate policies.
See More
Insulet Corporation Reports Strong Q4 2025 Earnings with Continued Growth
- Sustained Growth: Insulet reported $784 million in revenue for Q4 2025, reflecting a 29% year-over-year increase, marking the tenth consecutive year of over 20% revenue growth, showcasing its robust recurring revenue model and profitability.
- Market Expansion: The company achieved record new customer starts for Omnipod 5 in both U.S. and international markets, particularly in the type 2 diabetes segment, with the prescriber base expanding by 62% to over 6,500 clinicians, underscoring its leadership in diabetes management.
- Increased R&D Investment: R&D spending surged by 50% in Q4 2025, with plans to further increase investments in 2026 to advance next-generation platforms, including Omnipod 6 and a fully closed-loop system, aimed at enhancing patient experience and clinical outcomes.
- Optimistic Outlook: Insulet expects Omnipod revenue to grow by 21% to 23% in 2026, with total company revenue projected to increase by 20% to 22%, alongside an anticipated adjusted EPS growth of over 25%, reflecting strong confidence in future growth.
See More
Insulet Reports Strong Q4 Earnings and 2026 Guidance
- Strong Performance: Insulet's fourth-quarter adjusted earnings reached $1.55 per share, surpassing the market expectation of $1.45, demonstrating the company's robust profitability and competitive position in the market.
- Significant Sales Growth: The company reported sales of $783.8 million, a 31.2% year-over-year increase, and a 29% rise in constant currency, exceeding the market consensus of $768.69 million, indicating strong demand for its products.
- Expanded Buyback Plan: Insulet's board approved a $350 million increase in share repurchase authorization, with approximately $300 million expected to be allocated for repurchases in Q1 2026, reflecting the company's strong financial flexibility and sound financial health.
- Optimistic 2026 Outlook: Insulet forecasts 2026 sales between $3.250 billion and $3.304 billion, representing a year-over-year growth of 20%-22%, with plans for Omnipod products to grow by 21%-23%, showcasing the company's confidence in future market opportunities.
See More
Insulet Surges After Beating Q4 2025 Earnings Forecasts
- Earnings Beat: Insulet (PODD) reported Q4 2025 revenue of $783.8 million, a 29% YoY increase, surpassing consensus estimates by $15.1 million, indicating robust market performance.
- Sales Growth: Revenue from the Omnipod insulin pump surged approximately 42% in the U.S. and 28% internationally, reaching $567.8 million and $214.0 million respectively, reflecting strong global demand for the product.
- Profitability Improvement: Adjusted diluted EPS rose about 35% YoY to $1.55, beating consensus by $0.09, while adjusted operating margin increased to 19%, up 30 basis points from the previous year, showcasing enhanced profitability.
- Positive Outlook: Insulet forecasts adjusted EPS of $4.97 and revenue of $2.7 billion for 2025, representing YoY growth of approximately 54% and 30%, respectively, with continued strong growth expected into 2026, highlighting a favorable market outlook.
See More
US Stock Markets Rise on Strong Economic Data
- Strong Economic Data: US December capital goods new orders rose 0.6% month-over-month, surpassing expectations of 0.3%, indicating a rebound in capital spending and boosting market confidence in economic recovery.
- Housing Market Recovery: December housing starts increased by 6.2% month-over-month to 1.404 million, significantly exceeding expectations of 1.304 million, suggesting a revival in the real estate market that could drive growth in related sectors.
- Manufacturing Production Growth: January manufacturing production rose 0.6% month-over-month, beating expectations of 0.4%, marking the largest increase in 11 months, which indicates a recovery momentum in manufacturing that may further propel economic growth.
- Optimistic Corporate Earnings: Over 75% of S&P 500 companies reported earnings that exceeded expectations, with Q4 earnings growth projected at 8.4%, which will further boost market sentiment and attract investor interest.
See More
Insulet Stock Rises 10% Following Strong Q4 Results
- Stock Performance: Insulet shares increased by 10% following the release of their Q4 results.
- Earnings Report: The company's Q4 results exceeded market expectations, contributing to the rise in stock value.
See More
US Stocks Close Higher on Strong Economic Data
- Strong Economic Data: US December capital goods new orders rose 0.6% month-over-month, exceeding expectations of 0.3%, indicating a rebound in capital spending that boosts market confidence and drives stock prices higher.
- Housing Market Recovery: December housing starts increased by 6.2% month-over-month to 1.404 million, significantly surpassing the expected 1.304 million, suggesting a recovery in the housing market that could stimulate investment and consumption in related sectors.
- Manufacturing Production Growth: January manufacturing production rose by 0.6% month-over-month, stronger than the expected 0.4%, marking the largest increase in 11 months, indicating a recovery in manufacturing that supports overall economic growth expectations.
- Optimistic Stock Market Performance: Over 75% of S&P 500 companies reported earnings that beat expectations, with Q4 earnings growth projected at 8.4%, providing strong support for the stock market despite lingering doubts about future interest rate policies.
See More
Insulet Corporation Reports Strong Q4 2025 Earnings with Continued Growth
- Sustained Growth: Insulet reported $784 million in revenue for Q4 2025, reflecting a 29% year-over-year increase, marking the tenth consecutive year of over 20% revenue growth, showcasing its robust recurring revenue model and profitability.
- Market Expansion: The company achieved record new customer starts for Omnipod 5 in both U.S. and international markets, particularly in the type 2 diabetes segment, with the prescriber base expanding by 62% to over 6,500 clinicians, underscoring its leadership in diabetes management.
- Increased R&D Investment: R&D spending surged by 50% in Q4 2025, with plans to further increase investments in 2026 to advance next-generation platforms, including Omnipod 6 and a fully closed-loop system, aimed at enhancing patient experience and clinical outcomes.
- Optimistic Outlook: Insulet expects Omnipod revenue to grow by 21% to 23% in 2026, with total company revenue projected to increase by 20% to 22%, alongside an anticipated adjusted EPS growth of over 25%, reflecting strong confidence in future growth.
See More
Insulet Reports Strong Q4 Earnings and 2026 Guidance
- Strong Performance: Insulet's fourth-quarter adjusted earnings reached $1.55 per share, surpassing the market expectation of $1.45, demonstrating the company's robust profitability and competitive position in the market.
- Significant Sales Growth: The company reported sales of $783.8 million, a 31.2% year-over-year increase, and a 29% rise in constant currency, exceeding the market consensus of $768.69 million, indicating strong demand for its products.
- Expanded Buyback Plan: Insulet's board approved a $350 million increase in share repurchase authorization, with approximately $300 million expected to be allocated for repurchases in Q1 2026, reflecting the company's strong financial flexibility and sound financial health.
- Optimistic 2026 Outlook: Insulet forecasts 2026 sales between $3.250 billion and $3.304 billion, representing a year-over-year growth of 20%-22%, with plans for Omnipod products to grow by 21%-23%, showcasing the company's confidence in future market opportunities.
See More
Insulet Surges After Beating Q4 2025 Earnings Forecasts
- Earnings Beat: Insulet (PODD) reported Q4 2025 revenue of $783.8 million, a 29% YoY increase, surpassing consensus estimates by $15.1 million, indicating robust market performance.
- Sales Growth: Revenue from the Omnipod insulin pump surged approximately 42% in the U.S. and 28% internationally, reaching $567.8 million and $214.0 million respectively, reflecting strong global demand for the product.
- Profitability Improvement: Adjusted diluted EPS rose about 35% YoY to $1.55, beating consensus by $0.09, while adjusted operating margin increased to 19%, up 30 basis points from the previous year, showcasing enhanced profitability.
- Positive Outlook: Insulet forecasts adjusted EPS of $4.97 and revenue of $2.7 billion for 2025, representing YoY growth of approximately 54% and 30%, respectively, with continued strong growth expected into 2026, highlighting a favorable market outlook.
See More
US Stock Markets Rise on Strong Economic Data
- Strong Economic Data: US December capital goods new orders rose 0.6% month-over-month, surpassing expectations of 0.3%, indicating a rebound in capital spending and boosting market confidence in economic recovery.
- Housing Market Recovery: December housing starts increased by 6.2% month-over-month to 1.404 million, significantly exceeding expectations of 1.304 million, suggesting a revival in the real estate market that could drive growth in related sectors.
- Manufacturing Production Growth: January manufacturing production rose 0.6% month-over-month, beating expectations of 0.4%, marking the largest increase in 11 months, which indicates a recovery momentum in manufacturing that may further propel economic growth.
- Optimistic Corporate Earnings: Over 75% of S&P 500 companies reported earnings that exceeded expectations, with Q4 earnings growth projected at 8.4%, which will further boost market sentiment and attract investor interest.
See More
